Patrick G. LePore, Director at VYNE Therapeutics Inc. (NASDAQ:VYNE), recently acquired 15,000 shares of the company’s stock. The transaction, which occurred on January 15, 2025, was executed at a weighted average price of $2.92 per share, for a total of approximately $43,800. Purchase comes as InvestingPro data shows that the stock has fallen nearly 30% in the past week, with a current market capitalization of $38.8 million. Following this purchase, LePore now directly holds 51,472 shares. The shares were acquired in a series of transactions with prices ranging from $2.8776 to $2.9836. According to InvestingPro analysis, VYNE appears to be undervalued at current levels and maintains a strong financial position with more cash than debt on its balance sheet. Subscribers to InvestingPro can access 5 additional exclusive insights into VYNE’s financial health and growth prospects.
In other recent news, VYNE Therapeutics made significant progress in its clinical trials and financial results. The company completed enrollment in a Phase 2b trial for its vitiligo treatment, VYN201, earning a Maintain Buy rating from HC Wainwright and a $5.75 price target. Analyst consensus also supports a strong buy, with price targets ranging from $5.00 to $8.00.
BTIG also initiated coverage on VYNE Therapeutics, issuing a Buy rating and setting a $8.00 price target, noting the potential of the company’s lead program, VYN201. In addition, VYNE’s oral inhibitor, VYN202, is moving toward trials for psoriasis and rheumatoid arthritis.
Financially, VYNE reported a second-quarter loss per share of $0.22, but maintains a healthy financial position with $78.1 million in cash on hand to fund operations through 2025. TD Cowen and HC Wainwright maintained their Buy rating on the company.
These recent developments illustrate VYNE Therapeutics’ continued commitment to innovation and growth in the healthcare sector. The company also recently commenced dosing for a phase 2b trial of VYN201 in the treatment of vitiligo and secured a patent in the UK for its program compound VYN202. The main results of the trial are expected to be published in mid-2025.
This article was generated with the support of artificial intelligence and reviewed by an editor. See our T&C for more information.
